SLC12A1 Knockout Cell Line (Hela)

The choice depends on whether you are studying SLC12A1 (NKCC2)'s role as the apical Na⁺-K⁺-2Cl⁻ cotransporter in the thick ascending limb or modeling Bartter syndrome type 1. The Knockout line is the standard tool for asking whether NKCC2 is required for these transport activities — NKCC2 is the principal Na⁺ reabsorption transporter in the renal thick ascending limb and the molecular target of loop diuretics (furosemide, bumetanide). Overexpression is useful for studying disease-associated mutations or for testing diuretic specificity. Important context: NKCC2 is principally expressed in renal thick ascending limb — HeLa is not the physiological context for NKCC2 function. The EDITGENE Knockout in HeLa is most useful for in vitro biochemistry, structure-function studies, and as a clean background for heterologous NKCC2 reconstitution. SLC12A1 mutations cause Bartter syndrome type 1 (antenatal Bartter syndrome with severe salt-wasting) — disease variant rescue enables genotype-function studies. Rescue with wild-type, transport-deficient, or diuretic-resistant NKCC2 variants enables comprehensive functional characterization.

Primary applications: • Bartter syndrome modeling: rescue with patient-derived SLC12A1 mutations for genotype-function correlation studies of type 1 Bartter syndrome. • Loop diuretic pharmacology: furosemide, bumetanide, and torsemide specificity testing with the knockout as critical genetic control. • In vitro Na⁺-K⁺-2Cl⁻ cotransport: ³⁶Cl⁻ or ⁸⁶Rb⁺ flux measurements in heterologous NKCC2 expression. • Structure-function studies: rescue with NKCC2 splice variants (NKCC2-A, -B, -F) for variant-specific characterization. EDITGENE recommends this model for in vitro NKCC2 biochemistry, Bartter syndrome modeling, and loop diuretic pharmacology research.

Yes. NKCC2 rescue experiments are well-established for diuretic pharmacology and Bartter disease research: • Construct design: use a codon-modified SLC12A1 sequence with a small C-terminal tag (FLAG, HA). NKCC2 has 12 transmembrane domains with a large cytoplasmic C-terminus. • Splice variant-specific rescue: NKCC2-A, NKCC2-B, NKCC2-F variants have distinct kinetic properties — separate rescue enables variant-specific characterization. • Bartter syndrome rescue: patient-derived SLC12A1 mutations enable comprehensive disease genotype-function studies. • Functional readout: rescue should restore Na⁺-K⁺-2Cl⁻ cotransport activity measured by ⁸⁶Rb⁺ or ³⁶Cl⁻ flux assays. HeLa transduces efficiently with lentivirus and supports stable rescue line generation.